Compare Monster Beverage Corp (MNST) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs ResMed Inc. — how do they compare? Monster Beverage Corp trades at $94.22 (market cap $93.35B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: Monster Beverage Corp is far larger — about 3.2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.21% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | RMD | |
|---|---|---|
Market Cap | $93.35B | $28.81B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $293.73 |
52-Week Low | $58.75 | $182.82 |
Enterprise Value | $91.65B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $94.46, down 3.12% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.58 exceeding the $0.527 estimate, and maintains robust profitability with a net income margin of 23.11%. A 2-for-1 stock split is scheduled for August 2026, reflecting confidence in future growth.
The investment outlook is positive, driven by consistent earnings outperformance, international expansion, and product innovation. Risks include elevated valuation multiples (P/E of 46.11) and competitive pressures in the beverage sector. Analyst consensus is bullish with a $97.83 price target, suggesting modest upside from current levels.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
